AG
Artal Group Portfolio holdings
AUM
$930M
This Quarter Return
+21.99%
1 Year Return
-3.57%
3 Year Return
+157.23%
5 Year Return
+160.22%
10 Year Return
+1,359.85%
AUM
$6.8B
AUM Growth
+$6.8B
(+27%)
Cap. Flow
+$226M
Cap. Flow
% of AUM
3.33%
Top 10 Holdings %
Top 10 Hldgs %
92.21%
Holding
134
New
22
Increased
25
Reduced
13
Closed
23
Top Buys
| 1 |
ONC
BeOne Medicines Ltd. American Depositary Shares
ONC
|
$50.4M |
| 2 |
BPMC
Blueprint Medicines
BPMC
|
$32.1M |
| 3 |
Nektar Therapeutics
NKTR
|
$31.9M |
| 4 |
TSRO
TESARO, Inc.
TSRO
|
$28.6M |
| 5 |
Amicus Therapeutics
FOLD
|
$22.6M |
Top Sells
| 1 |
Neurocrine Biosciences
NBIX
|
$19.4M |
| 2 |
Incyte
INCY
|
$16.7M |
| 3 |
GBT
Global Blood Therapeutics, Inc.
GBT
|
$7.25M |
| 4 |
CLVS
Clovis Oncology, Inc.
CLVS
|
$6.8M |
| 5 |
ALDR
Alder Biopharmaceuticals, Inc.
ALDR
|
$5.73M |
Sector Composition
| 1 | Consumer Staples | 51.19% |
| 2 | Consumer Discretionary | 27.58% |
| 3 | Healthcare | 20.59% |
| 4 | Communication Services | 0.17% |
| 5 | Materials | 0.06% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
GBT
26
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $9.66M | 0.12% |
200,000
-150,000
| -43% | -$7.25M |
|
27
Xencor
XNCR
$594M
| $8.99M | 0.11% |
300,000
+200,000
| +200% | +$6M |
|
28
Larimar Therapeutics
LRMR
$337M
| $8.94M | 0.11% |
1,200,000
+200,000
| +20% | +$1.49M |
|
|
LJPC
29
DELISTED
La Jolla Pharmaceutical Company
LJPC
| $8.93M | 0.11% |
+300,000
| New | +$8.93M |
|
30
Denali Therapeutics
DNLI
$2.24B
| $8.86M | 0.11% |
450,000
-50,000
| -10% | -$985K |
|
31
Fate Therapeutics
FATE
$115M
| $8.3M | 0.1% |
+850,000
| New | +$8.3M |
|
|
ZGNX
32
DELISTED
Zogenix, Inc.
ZGNX
| $8.01M | 0.1% |
+200,000
| New | +$8.01M |
|
33
Iovance Biotherapeutics
IOVA
$800M
| $7.77M | 0.1% |
+460,000
| New | +$7.77M |
|
34
Regenxbio
RGNX
$498M
| $7.46M | 0.09% |
250,000
| – | – |
|
35
Immunic
IMUX
$79.4M
| $6.8M | 0.09% |
1,000,000
+125,000
| +14% | +$850K |
|
|
MDCO
36
DELISTED
Medicines Co
MDCO
| $6.59M | 0.08% |
200,000
| – | – |
|
37
AC Immune
ACIU
$227M
| $6.2M | 0.08% |
600,000
+100,000
| +20% | +$1.03M |
|
|
STML
38
DELISTED
Stemline Therapeutics, Inc.
STML
| $6.12M | 0.08% |
400,000
+200,000
| +100% | +$3.06M |
|
39
Wave Life Sciences
WVE
$1.27B
| $6.02M | 0.08% |
150,000
+57,922
| +63% | +$2.32M |
|
40
ProQR Therapeutics
PRQR
$256M
| $5.84M | 0.07% |
1,900,000
| – | – |
|
|
CBIO
41
Crescent Biopharma, Inc. Common Stock
CBIO
$184M
| $5.28M | 0.07% |
325,000
+75,000
| +30% | +$1.22M |
|
42
Madrigal Pharmaceuticals
MDGL
$9.7B
| $5.26M | 0.07% |
+45,000
| New | +$5.26M |
|
|
CBAY
43
DELISTED
Cymabay Therapeutics
CBAY
| $5.2M | 0.07% |
+400,000
| New | +$5.2M |
|
|
KDNY
44
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
| $5.12M | 0.06% |
550,000
+350,000
| +175% | +$3.26M |
|
|
ACGN
45
DELISTED
Aceragen, Inc. Common Stock
ACGN
| $5.06M | 0.06% |
+2,750,000
| New | +$5.06M |
|
46
Spero Therapeutics
SPRO
$117M
| $4.99M | 0.06% |
350,000
| – | – |
|
47
Rocket Pharmaceuticals
RCKT
$358M
| $4.69M | 0.06% |
+250,000
| New | +$4.69M |
|
48
Arcus Biosciences
RCUS
$1.24B
| $4.63M | 0.06% |
+300,000
| New | +$4.63M |
|
49
Akebia Therapeutics
AKBA
$827M
| $4.53M | 0.06% |
+475,000
| New | +$4.53M |
|
|
BOLD
50
DELISTED
Audentes Therapeutics, Inc
BOLD
| $4.51M | 0.06% |
150,000
-50,000
| -25% | -$1.5M |
|